Article Link: FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients ...
FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel
Article Link: FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel INCHEON, Korea – As of April 2019 – Samsung Bioepis Co., Ltd...
FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel (etanercept)
Article Link: FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel (etanercept) April 26, 2019 The FDA has approved Eticovo (et...
GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above
Article Link: GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above London UK, Philad...
FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
Article Link: FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization PARIS and ...
FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults
Article Link: FDA Approves Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis In Adults LAVAL, Queb...
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
Article Link: FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis NORTH CHICAGO, Ill., April 23, 2019 /PRNew...
FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC
Article Link: FDA Approves Expanded Monotherapy Label for Merck’s Keytruda (pembrolizumab) for First-Line Treatment of NSCLC KENILWORTH, ...
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer
Article Link: FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer April 12, 2019 — The U.S. Food and...
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture
Article Link: FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture ...
